Evaluating Rates of Recurrent Ischemic Stroke Among Young Adults With Embolic Stroke of Undetermined Source: The Young ESUS Longitudinal Cohort Study.

Perera, Kanjana S; de Sa Boasquevisque, Danielle; Rao-Melacini, Purnima; Taylor, Amanda; Cheng, Anna; Hankey, Graeme J; Lee, Sarah; Fabregas, Joan Marti; Ameriso, Sebastian F; Field, Thalia S; Arauz, Antonio; Coutts, Shelagh B; Arnold, Marcel; Mikulik, Robert; Toni, Danilo; Mandzia, Jennifer; Veltkamp, Roland C; Meseguer, Elena; Haeusler, Karl Georg and Hart, Robert G (2022). Evaluating Rates of Recurrent Ischemic Stroke Among Young Adults With Embolic Stroke of Undetermined Source: The Young ESUS Longitudinal Cohort Study. JAMA neurology, 79(5), pp. 450-458. American Medical Association 10.1001/jamaneurol.2022.0048

[img] Text
Perera__2022__Evaluating_Rates_of_Recurrent_Ischemic_Stroke.pdf - Published Version
Restricted to registered users only
Available under License Publisher holds Copyright.

Download (296kB) | Request a copy

Importance

Cryptogenic strokes constitute approximately 40% of ischemic strokes in young adults, and most meet criteria for the embolic stroke of undetermined source (ESUS). Two randomized clinical trials, NAVIGATE ESUS and RESPECT ESUS, showed a high rate of stroke recurrence in older adults with ESUS but the prognosis and prognostic factors among younger individuals with ESUS is uncertain.

Objective

To determine rates of and factors associated with recurrent ischemic stroke and death and new-onset atrial fibrillation (AF) among young adults.

Design, Setting, and Participants

This multicenter longitudinal cohort study with enrollment from October 2017 to October 2019 and a mean follow-up period of 12 months ending in October 2020 included 41 stroke research centers in 13 countries. Consecutive patients 50 years and younger with a diagnosis of ESUS were included. Of 576 screened, 535 participants were enrolled after 1 withdrew consent, 41 were found to be ineligible, and 2 were excluded for other reasons. The final follow-up visit was completed by 520 patients.

Main Outcomes and Measures

Recurrent ischemic stroke and/or death, recurrent ischemic stroke, and prevalence of patent foramen ovale (PFO).

Results

The mean (SD) age of participants was 40.4 (7.3) years, and 297 (56%) participants were male. The most frequent vascular risk factors were tobacco use (240 patients [45%]), hypertension (118 patients [22%]), and dyslipidemia (109 patients [20%]). PFO was detected in 177 participants (50%) who had transthoracic echocardiograms with bubble studies. Following initial ESUS, 468 participants (88%) were receiving antiplatelet therapy, and 52 (10%) received anticoagulation. The recurrent ischemic stroke and death rate was 2.19 per 100 patient-years, and the ischemic stroke recurrence rate was 1.9 per 100 patient-years. Of the recurrent strokes, 9 (64%) were ESUS, 2 (14%) were cardioembolic, and 3 (21%) were of other determined cause. AF was detected in 15 participants (2.8%; 95% CI, 1.6-4.6). In multivariate analysis, the following were associated with recurrent ischemic stroke: history of stroke or transient ischemic attack (hazard ratio, 5.3; 95% CI, 1.8-15), presence of diabetes (hazard ratio, 4.4; 95% CI, 1.5-13), and history of coronary artery disease (hazard ratio, 10; 95% CI, 4.8-22).

Conclusions and Relevance

In this large cohort of young adult patients with ESUS, there was a relatively low rate of subsequent ischemic stroke and a low frequency of new-onset AF. Most recurrent strokes also met the criteria for ESUS, suggesting the need for future studies to improve our understanding of the underlying stroke mechanism in this population.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Head Organs and Neurology (DKNS) > Clinic of Neurology

UniBE Contributor:

Arnold, Marcel

Subjects:

600 Technology > 610 Medicine & health

ISSN:

2168-6157

Publisher:

American Medical Association

Language:

English

Submitter:

Chantal Kottler

Date Deposited:

03 Nov 2022 12:02

Last Modified:

05 Dec 2022 16:27

Publisher DOI:

10.1001/jamaneurol.2022.0048

PubMed ID:

35285869

BORIS DOI:

10.48350/174464

URI:

https://boris.unibe.ch/id/eprint/174464

Actions (login required)

Edit item Edit item
Provide Feedback